A unified approach for subgroup identification and individualized treatment recommendation with applications to randomized control trials and observational studies
暂无分享,去创建一个
[1] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[2] J. Robins,et al. Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .
[3] D. Horvitz,et al. A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .
[4] Sara T Brookes,et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.
[5] D. Zeng,et al. Recent development on statistical methods for personalized medicine discovery , 2013, Frontiers of Medicine.
[6] Michael R. Kosorok,et al. Robust Hybrid Learning for Estimating Personalized Dynamic Treatment Regimens , 2016, 1611.02314.
[7] L. Tian,et al. Analysis of randomized comparative clinical trial data for personalized treatment selections. , 2011, Biostatistics.
[8] Craig D. Shriver,et al. Breast Cancer in the Personal Genomics Era , 2010, Current genomics.
[9] Lei Chen,et al. The mean does not mean as much anymore: finding sub-groups for tailored therapeutics , 2010, Clinical trials.
[10] J. M. Taylor,et al. Subgroup identification from randomized clinical trial data , 2011, Statistics in medicine.
[11] S. Lagakos. The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.
[12] I. Lipkovich,et al. Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations , 2011, Statistics in medicine.
[13] Xiaogang Su,et al. Subgroup Analysis via Recursive Partitioning , 2009 .
[14] M. Hanefeld,et al. A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[15] M. Cronin,et al. Pharmacogenomics: The promise of personalized medicine , 2000, AAPS PharmSci.
[16] J. O’Connell,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.
[17] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[18] Susan A. Murphy,et al. A Generalization Error for Q-Learning , 2005, J. Mach. Learn. Res..
[19] Ilya Lipkovich,et al. Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder , 2013, International journal of methods in psychiatric research.
[20] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[21] Dirk Eddelbuettel,et al. Rcpp: Seamless R and C++ Integration , 2011 .
[22] Donglin Zeng,et al. Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.
[23] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[24] Lu Tian,et al. Effectively Selecting a Target Population for a Future Comparative Study , 2013, Journal of the American Statistical Association.
[25] S. Murphy,et al. PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. , 2011, Annals of statistics.
[26] S. Hunt,et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.